Several studies demonstrated that oxidative damage is a characteristic feature of many neurodegenerative diseases. The accumulation of oxidatively modified proteins may disrupt cellular functions by affecting protein expression, protein turnover, cell signaling, and induction of apoptosis and necrosis, suggesting that protein oxidation could have both physiological and pathological significance. For nearly two decades, our laboratory focused particular attention on studying oxidative damage of proteins and how their chemical modifications induced by reactive oxygen species/reactive nitrogen species correlate with pathology, biochemical alterations, and clinical presentations of Alzheimer's disease. This comprehensive article outlines basic knowledge of oxidative modification of proteins and lipids, followed by the principles of redox proteomics analysis, which also involve recent advances of mass spectrometry technology, and its application to selected age-related neurodegenerative diseases. Redox proteomics results obtained in different diseases and animal models thereof may provide new insights into the main mechanisms involved in the pathogenesis and progression of oxidative-stress-related neurodegenerative disorders. Redox proteomics can be considered a multifaceted approach that has the potential to provide insights into the molecular mechanisms of a disease, to find disease markers, as well as to identify potential targets for drug therapy. Considering the importance of a better understanding of the cause/effect of protein dysfunction in the pathogenesis and progression of neurodegenerative disorders, this article provides an overview of the intrinsic power of the redox proteomics approach together with the most significant results obtained by our laboratory and others during almost 10 years of research on neurodegenerative disorders since we initiated the field of redox proteomics. Antioxid. Redox Signal. 17, 1610–1655.
AbboudK, BassilaJC, Ghali-GhoulR, SabraR. Temporal changes in vascular reactivity in early diabetes mellitus in rats: role of changes in endothelial factors and in phosphodiesterase activity. Am J Physiol Heart Circ Physiol, 297:H836–H845. 2009.
2.
AbeK, PanLH, WatanabeM, KatoT, ItoyamaY. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci Lett, 199:152–154. 1995.
3.
AbeK, PanLH, WatanabeM, KonnoH, KatoT, ItoyamaY. Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Neurol Res, 19:124–128. 1997.
4.
AbelloN, BarrosoB, KerstjensHA, PostmaDS, BischoffR. Chemical labeling and enrichment of nitrotyrosine-containing peptides. Talanta, 80:1503–1512. 2010.
5.
AdibhatlaRM, HatcherJF. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal, 12:125–169. 2010.
6.
AksenovM, AksenovaM, ButterfieldDA, MarkesberyWR. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J Neurochem, 74:2520–2527. 2000.
7.
AksenovMY, TuckerHM, NairP, AksenovaMV, ButterfieldDA, EstusS, MarkesberyWR. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. J Mol Neurosci, 11:151–164. 1998.
8.
AksenovaMV, BurbaevaG. [BB creatine kinase isoenzyme activity in the blood serum of patients with senile dementia, Alzheimer's disease and schizophrenia]Zh Nevropatol Psikhiatr Im S S Korsakova, 89:113–116. 1989.
9.
AlamZI, JennerA, DanielSE, LeesAJ, CairnsN, MarsdenCD, JennerP, HalliwellB. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem, 69:1196–1203. 1997.
10.
AluiseCD, RobinsonRA, CaiJ, PierceWM, MarkesberyWR, ButterfieldDA. Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. J Alzheimers Dis, 23:257–269. 2011.
11.
AlvarezB, RadiR. Peroxynitrite reactivity with amino acids and proteins. Amino Acids, 25:295–311. 2003.
12.
AndersenJK. Iron dysregulation and Parkinson's disease. J Alzheimers Dis, 6:S47–S52. 2004.
13.
AndersenPM. Genetic factors in the early diagnosis of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord, 1,Suppl 1:S31–S42. 2000.
14.
AndreassenOA, DedeogluA, FerranteRJ, JenkinsBG, FerranteKL, ThomasM, FriedlichA, BrowneSE, SchillingG, BorcheltDR, HerschSM, RossCA, BealMF. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis, 8:479–491. 2001.
15.
AndrusPK, FleckTJ, GurneyME, HallED. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem, 71:2041–2048. 1998.
16.
AnilkumarN, ParsonsM, MonkR, NgT, AdamsJC. Interaction of fascin and protein kinase C alpha: a novel intersection in cell adhesion and motility. EMBO J, 22:5390–5402. 2003.
17.
AnsariMA, JoshiG, HuangQ, OpiiWO, AbdulHM, SultanaR, ButterfieldDA. In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: relevance to Alzheimer's disease and other oxidative stress-related neurodegenerative disorders. Free Radic Biol Med, 41:1694–1703. 2006.
18.
AnsariMA, ScheffSW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol, 69:155–167. 2010.
ArendtT. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the “Dr. Jekyll and Mr. Hyde concept” of Alzheimer's disease or the yin and yang of neuroplasticity. Prog Neurobiol, 71:83–248. 2003.
21.
ArimaK, OgawaM, SunoharaN, NishioT, ShimomuraY, HiraiS, EtoK. Immunohistochemical and ultrastructural characterization of ubiquitinated eosinophilic fibrillary neuronal inclusions in sporadic amyotrophic lateral sclerosis. Acta Neuropathol, 96:75–85. 1998.
22.
AulakKS, KoeckT, CrabbJW, StuehrDJ. Proteomic method for identification of tyrosine-nitrated proteins. Methods Mol Biol, 279:151–165. 2004.
23.
Bader LangeML, CeniniG, PiroddiM, AbdulHM, SultanaR, GalliF, MemoM, ButterfieldDA. Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol Dis, 29:456–464. 2008.
24.
Bader LangeML, St. ClairD, MarkesberyWR, StudzinskiCM, MurphyMP, ButterfieldDA. Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiol Dis, 38:104–115. 2010.
25.
BailletA, ChanteperdrixV, TrocmeC, CasezP, GarrelC, BessonG. The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson's disease. Neurochem Res, 35:1530–1537. 2010.
26.
BalczB, KirchnerL, CairnsN, FountoulakisM, LubecG. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transm Suppl61:193–201. 2001.
BaloyannisSJ, CostaV, MauroudisI, PsaroulisD, ManolidesSL, ManolidesLS. Dendritic and spinal pathology in the acoustic cortex in Alzheimer's disease: morphological and morphometric estimation by Golgi technique and electron microscopy. Acta Otolaryngol, 127:351–354. 2007.
29.
BarberSC, ShawPJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med, 48:629–641. 2010.
30.
BartelsT, ChoiJG, SelkoeDJ. Alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature, 477:107–110. 2011.
31.
BassoM, GiraudoS, CorpilloD, BergamascoB, LopianoL, FasanoM. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics, 4:3943–3952. 2004.
32.
BassoM, SamengoG, NardoG, MassignanT, D'AlessandroG, TartariS, CantoniL, MarinoM, CheroniC, De BiasiS, GiordanaMT, StrongMJ, EstevezAG, SalmonaM, BendottiC, BonettoV. Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS One, 4:e8130. 2009.
33.
BattainiF, PascaleA, LucchiL, PasinettiGM, GovoniS. Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients. Exp Neurol, 159:559–564. 1999.
34.
BatyJW, HamptonMB, WinterbournCC. Detection of oxidant sensitive thiol proteins by fluorescence labeling and two-dimensional electrophoresis. Proteomics, 2:1261–1266. 2002.
35.
BayirH, KaganVE, ClarkRS, Janesko-FeldmanK, RafikovR, HuangZ, ZhangX, VagniV, BilliarTR, KochanekPM. Neuronal NOS-mediated nitration and inactivation of manganese superoxide dismutase in brain after experimental and human brain injury. J Neurochem, 101:168–181. 2007.
36.
BealMF, FerranteRJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci, 5:373–384. 2004.
37.
BeasleyA, AndersonC, McArthurJ, SacktorN, NathA, CotterJR. Characterization of nitrotyrosine-modified proteins in cerebrospinal fluid. Clin Proteomics, 6:29–41. 2010.
38.
BeckmanJS, ChenJ, CrowJP, YeYZ. Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog Brain Res, 103:371–380. 1994.
39.
BergD, YoudimMB. Role of iron in neurodegenerative disorders. Top Magn Reson Imaging, 17:5–17. 2006.
40.
BerlettBS, StadtmanER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem, 272:20313–20316. 1997.
41.
BiglM, BrucknerMK, ArendtT, BiglV, EschrichK. Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease. J Neural Trans, 106:499–511. 1999.
42.
BogdanovMB, AndreassenOA, DedeogluA, FerranteRJ, BealMF. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem, 79:1246–1249. 2001.
43.
BogdanovicN, ZilmerM, ZilmerK, RehemaA, KarelsonE. The Swedish APP670/671 Alzheimer's disease mutation: the first evidence for strikingly increased oxidative injury in the temporal inferior cortex. Dement Geriatr Cogn Disord, 12:364–370. 2001.
44.
BommerUA, BorovjaginAV, GreaggMA, JeffreyIW, RussellP, LaingKG, LeeM, ClemensMJ. The mRNA of the translationally controlled tumor protein P23/TCTP is a highly structured RNA, which activates the dsRNA-dependent protein kinase PKR. RNA, 8:478–496. 2002.
45.
BonillaE, EstevezJ, SuarezH, MoralesLM, Chacin de BonillaL, VillalobosR, DavilaJO. Serum ferritin deficiency in Huntington's disease patients. Neurosci Lett, 129:22–24. 1991.
46.
BoniniNM, GiassonBI. Snaring the function of alpha-synuclein. Cell, 123:359–361. 2005.
47.
BoscoDA, MorfiniG, KarabacakNM, SongY, Gros-LouisF, PasinelliP, GoolsbyH, FontaineBA, LemayN, McKenna-YasekD, FroschMP, AgarJN, JulienJP, BradyST, BrownRHJr.Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci, 13:1396–1403. 2010.
48.
BosettiF, BrizziF, BarogiS, MancusoM, SicilianoG, TendiEA, MurriL, RapoportSI, SolainiG. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging, 23:371–376. 2002.
49.
BowlingAC, SchulzJB, BrownRHJr., BealMF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem, 61:2322–2325. 1993.
50.
Boyd-KimballD, CastegnaA, SultanaR, PoonHF, PetrozeR, LynnBC, KleinJB, ButterfieldDA. Proteomic identification of proteins oxidized by Abeta(1–42) in synaptosomes: implications for Alzheimer's disease. Brain Res, 1044:206–215. 2005.
51.
BradleyMA, MarkesberyWR, LovellMA. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med, 48:1570–1576. 2010.
52.
BrowneSE. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann N Y Acad Sci, 1147:358–382. 2008.
BrueningW, RoyJ, GiassonB, FiglewiczDA, MushynskiWE, DurhamHD. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J Neurochem, 72:693–699. 1999.
58.
BubberP, HaroutunianV, FischG, BlassJP, GibsonGE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol, 57:695–703. 2005.
59.
BueeL, BussiereT, Buee-ScherrerV, DelacourteA, HofPR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev, 33:95–130. 2000.
60.
BurkhardPR, SanchezJC, LandisT, HochstrasserDF. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology, 56:1528–1533. 2001.
61.
BusciglioJ, PelsmanA, WongC, PiginoG, YuanM, MoriH, YanknerBA. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron, 33:677–688. 2002.
62.
ButterfieldD, CastegnaA, PocernichC, DrakeJ, ScapagniniG, CalabreseV. Nutritional approaches to combat oxidative stress in Alzheimer's disease. J Nutr Biochem, 13:444. 2002.
63.
ButterfieldDA. beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol, 10:495–506. 1997.
64.
ButterfieldDA, GnjecA, PoonHF, CastegnaA, PierceWM, KleinJB, MartinsRN. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: An initial assessment. J Alzheimers Dis, 10:391–397. 2006.
ButterfieldDA, Bader LangeML, SultanaR. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta, 1801:924–929. 2010.
67.
ButterfieldDA, Boyd-KimballD. The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta, 1703:149–156. 2005.
68.
ButterfieldDA, CastegnaA. Proteomics for the identification of specifically oxidized proteins in brain: technology and application to the study of neurodegenerative disorders. Amino Acids, 25:419–425. 2003.
69.
ButterfieldDA, DrakeJ, PocernichC, CastegnaA. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med, 7:548–554. 2001.
70.
ButterfieldDA, GalvanV, LangeMB, TangH, SowellRA, SpilmanP, FombonneJ, GorostizaO, ZhangJ, SultanaR, BredesenDE. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med, 48:136–144. 2010.
71.
ButterfieldDA, HardasSS, LangeML. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration. J Alzheimers Dis, 20:369–393. 2010.
72.
ButterfieldDA, HensleyK, ColeP, SubramaniamR, AksenovM, AksenovaM, BummerPM, HaleyBE, CarneyJM. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J Neurochem, 68:2451–2457. 1997.
73.
ButterfieldDA, LangeML. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem, 111:915–933. 2009.
74.
ButterfieldDA, LauderbackCM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med, 32:1050–1060. 2002.
75.
ButterfieldDA, PerluigiM, SultanaR. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol, 545:39–50. 2006.
76.
ButterfieldDA, PoonHF, St. ClairD, KellerJN, PierceWM, KleinJB, MarkesberyWR. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis, 22:223–232. 2006.
77.
ButterfieldDA, ReedT, NewmanSF, SultanaR. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med, 43:658–677. 2007.
78.
ButterfieldDA, ReedT, PerluigiM, De MarcoC, CocciaR, CiniC, SultanaR. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett, 397:170–173. 2006.
79.
ButterfieldDA, StadtmanER. Protein oxidation processes in aging brain. Adv Cell Aging Gerontol, 2:161–191. 1997.
80.
ButterfieldDA, SultanaR. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis, 12:61–72. 2007.
81.
CalabreseV. Highlight Commentary on Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice—a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med, 43:160–162. 2007.
82.
CalabreseV, MancusoC, CalvaniM, RizzarelliE, ButterfieldDA, StellaAM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci, 8:766–775. 2007.
83.
CalabreseV, ScapagniniG, ColombritaC, RavagnaA, PennisiG, Giuffrida StellaAM, GalliF, ButterfieldDA. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids, 25:437–444. 2003.
84.
CalabreseV, ScapagniniG, RavagnaA, ColombritaC, SpadaroF, ButterfieldDA, Giuffrida StellaAM. Increased expression of heat shock proteins in rat brain during aging: relationship with mitochondrial function and glutathione redox state. Mech Ageing Dev, 125:325–335. 2004.
85.
Canet-AvilesRM, WilsonMA, MillerDW, AhmadR, McLendonC, BandyopadhyayS, BaptistaMJ, RingeD, PetskoGA, CooksonMR. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A, 101:9103–9108. 2004.
86.
CapernaTJ, ShannonAE, Blomberg leA, GarrettWM, RamsayTG. Identification of protein carbonyls in serum of the fetal and neonatal pig. Comp Biochem Physiol B Biochem Mol Biol, 156:189–196. 2010.
87.
CasadoA, Encarnacion Lopez-FernandezM, Concepcion CasadoM, de La TorreR. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res, 33:450–458. 2008.
88.
CasagrandeS, BonettoV, FratelliM, GianazzaE, EberiniI, MassignanT, SalmonaM, ChangG, HolmgrenA, GhezziP. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci U S A, 99:9745–9749. 2002.
89.
CasoniF, BassoM, MassignanT, GianazzaE, CheroniC, SalmonaM, BendottiC, BonettoV. Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J Biol Chem, 280:16295–16304. 2005.
90.
CassinaAM, HodaraR, SouzaJM, ThomsonL, CastroL, IschiropoulosH, FreemanBA, RadiR. Cytochrome c nitration by peroxynitrite. J Biol Chem, 275:21409–21415. 2000.
91.
CastegnaA, AksenovM, AksenovaM, ThongboonkerdV, KleinJB, PierceWM, BoozeR, MarkesberyWR, ButterfieldDA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med, 33:562–571. 2002.
92.
CastegnaA, AksenovM, ThongboonkerdV, KleinJB, PierceWM, BoozeR, MarkesberyWR, ButterfieldDA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem, 82:1524–1532. 2002.
93.
CastegnaA, ThongboonkerdV, KleinJB, LynnB, MarkesberyWR, ButterfieldDA. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem, 85:1394–1401. 2003.
94.
CaudleWM, PanS, ShiM, QuinnT, HoekstraJ, BeyerRP, MontineTJ, ZhangJ. Proteomic identification of proteins in the human brain: towards a more comprehensive understanding of neurodegenerative disease. Proteomics Clin Appl, 2:1484–1497. 2008.
95.
CeniniG, DowlingALS, BeckettT, BaroneE, MancusoC, MurphyMP, LevineHIII, SchmittFA, ButterfieldDA, HeadE. Association between frontal cortex oxidative damage and beta-amyloid neuropathology as a function of age in Down syndrome. Biochem Biophys Acta, 1822:130–138. 2011.
96.
CharkoudianLK, FranzKJ. Fe(III)-coordination properties of neuromelanin components: 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid. Inorg Chem, 45:3657–3664. 2006.
97.
ChavezJ, ChungWG, MirandaCL, SinghalM, StevensJF, MaierCS. Site-specific protein adducts of 4-hydroxy-2(E)-nonenal in human THP-1 monocytic cells: protein carbonylation is diminished by ascorbic acid. Chem Res Toxicol, 23:37–47. 2010.
98.
ChavezJ, WuJ, HanB, ChungWG, MaierCS. New role for an old probe: affinity labeling of oxylipid protein conjugates by N'-aminooxymethylcarbonylhydrazino d-biotin. Anal Chem, 78:6847–6854. 2006.
99.
ChenQ, SurmeierDJ, ReinerA. NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization. Exp Neurol, 159:283–296. 1999.
100.
ChenZH, SaitoY, YoshidaY, SekineA, NoguchiN, NikiE. 4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J Biol Chem, 280:41921–41927. 2005.
101.
ChiappettaG, CorboC, PalmeseA, GalliF, PiroddiM, MarinoG, AmoresanoA. Quantitative identification of protein nitration sites. Proteomics, 9:1524–1537. 2009.
102.
ChoiDE, JeongJY, LimBJ, ChungS, ChangYK, LeeSJ, NaKR, KimSY, ShinYT, LeeKW. Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol, 297:F362–F370. 2009.
103.
ChoiJ, LeveyAI, WeintraubST, ReesHD, GearingM, ChinLS, LiL. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem, 279:13256–13264. 2004.
104.
CiminiA, MorenoS, D'AmelioM, CristianoL, D'AngeloB, FaloneS, BenedettiE, CarraraP, FanelliF, CecconiF, AmicarelliF, CeruMP. Early biochemical and morphological modifications in the brain of a transgenic mouse model of Alzheimer's disease: a role for peroxisomes. J Alzheimers Dis, 18:935–952. 2009.
105.
ClementiME, PezzottiM, OrsiniF, SampaoleseB, MezzogoriD, GrassiC, GiardinaB, MisitiF. Alzheimer's amyloid beta-peptide (1–42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: an intriguing role for methionine 35. Biochem Biophys Res Commun, 342:206–213. 2006.
106.
ClevelandDW, RothsteinJD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci, 2:806–819. 2001.
107.
ColemanPD, FloodDG. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging, 8:521–545. 1987.
108.
ConnorJR, SnyderBS, BeardJL, FineRE, MufsonEJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res, 31:327–335. 1992.
109.
CrichtonRR, PierreJL. Old iron, young copper: from Mars to Venus. Biometals, 14:99–112. 2001.
110.
CruthirdsDL, NovakL, AkhiKM, SandersPW, ThompsonJA, MacMillan-CrowLA. Mitochondrial targets of oxidative stress during renal ischemia/reperfusion. Arch Biochem Biophys, 412:27–33. 2003.
111.
CurtiD, MalaspinaA, FacchettiG, CamanaC, MazziniL, ToscaP, ZerbiF, CeroniM. Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Neurology, 47:1060–1064. 1996.
112.
D'AlessandroA, RinalducciS, ZollaL. Redox proteomics and drug development. J Proteomics, 74:2575–2595. 2011.
113.
Dalle-DonneI. Familial amyotrophic lateral sclerosis (FALS): Emerging hints from redox proteomics. Highlight commentary on: “Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice—a model of familial amyotrophic lateral sclerosis”Free Radic Biol Med, 43:157–159. 2007.
114.
Dalle-DonneI, GiustariniD, ColomboR, RossiR, MilzaniA. Protein carbonylation in human diseases. Trends Mol Med, 9:169–176. 2003.
115.
Dalle-DonneI, ScaloniA, ButterfieldDA. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases. Hoboken, NJ: John Wiley and Sons, 2006.
116.
DalyNL, HoffmannR, OtvosLJr., CraikDJ. Role of phosphorylation in the conformation of tau peptides implicated in Alzheimer's disease. Biochemistry, 39:9039–9046. 2000.
117.
DavidS, ShoemakerM, HaleyBE. Abnormal properties of creatine kinase in Alzheimer's disease brain: correlation of reduced enzyme activity and active site photolabeling with aberrant cytosol-membrane partitioning. Brain Res Mol Brain Res, 54:276–287. 1998.
118.
DaviesKJ, ShringarpureR. Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases. Neurology, 66:S93–S96. 2006.
119.
DaviesP, MouallaD, BrownDR. Alpha-synuclein is a cellular ferrireductase. PLoS One, 6:e15814. 2011.
120.
De IuliisA, GrigolettoJ, RecchiaA, GiustiP, ArslanP. A proteomic approach in the study of an animal model of Parkinson's disease. Clin Chim Acta, 357:202–209. 2005.
121.
DemicheliV, QuijanoC, AlvarezB, RadiR. Inactivation and nitration of human superoxide dismutase (SOD) by fluxes of nitric oxide and superoxide. Free Radic Biol Med, 42:1359–1368. 2007.
122.
DexterDT, JennerP, SchapiraAH, MarsdenCD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol, 32,Suppl:S94–S100. 1992.
123.
Di DomenicoF, SultanaR, TiuGF, ScheffNN, PerluigiM, CiniC, ButterfieldDA. Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Res, 1333:72–81. 2010.
124.
Di StasiAM, MallozziC, MacchiaG, PetrucciTC, MinettiM. Peroxynitrite induces tryosine nitration and modulates tyrosine phosphorylation of synaptic proteins. J Neurochem, 73:727–735. 1999.
125.
DiamandisEP, ChristopoulosTK. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem, 37:625–636. 1991.
126.
DiFigliaM, SappE, ChaseKO, DaviesSW, BatesGP, VonsattelJP, AroninN. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277:1990–1993. 1997.
127.
DingB, ChenKM, LingHW, SunF, LiX, WanT, ChaiWM, ZhangH, ZhanY, GuanYJ. Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease. J Magn Reson Imaging, 29:793–798. 2009.
128.
DingQ, MarkesberyWR, CecariniV, KellerJN. Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochem Res, 31:705–710. 2006.
129.
DoornJA, MaserE, BlumA, ClaffeyDJ, PetersenDR. Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal. Biochemistry, 43:13106–13114. 2004.
130.
DoornJA, PetersenDR. Covalent adduction of nucleophilic amino acids by 4-hydroxynonenal and 4-oxononenal. Chem Biol Interact, 143–144:93–100. 2003.
131.
DrakeJ, LinkCD, ButterfieldDA. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1–42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging, 24:415–420. 2003.
132.
DuanZ, LamendolaDE, YusufRZ, PensonRT, PrefferFI, SeidenMV. Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res, 22:1933–1941. 2002.
133.
DuceJA, TsatsanisA, CaterMA, JamesSA, RobbE, WikheK, LeongSL, PerezK, JohanssenT, GreenoughMA, ChoHH, GalatisD, MoirRD, MastersCL, McLeanC, TanziRE, CappaiR, BarnhamKJ, CiccotostoGD, RogersJT, BushAI. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell, 142:857–867. 2010.
134.
DumontM, WilleE, StackC, CalingasanNY, BealMF, LinMT. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J, 23:2459–2466. 2009.
135.
DuyckaertsC, DelatourB, PotierMC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol, 118:5–36. 2009.
136.
EismannT, HuberN, ShinT, KubokiS, GallowayE, WyderM, EdwardsMJ, GreisKD, ShertzerHG, FisherAB, LentschAB. Peroxiredoxin-6 protects against mitochondrial dysfunction and liver injury during ischemia-reperfusion in mice. Am J Physiol Gastrointest Liver Physiol, 296:G266–G274. 2009.
137.
El Tannir El TayaraN, DelatourB, Le CudennecC, GueganM, VolkA, DhenainM. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis, 22:199–208. 2006.
138.
EliukSM, RenfrowMB, ShonseyEM, BarnesS, KimH. Active site modifications of the brain isoform of creatine kinase by 4-hydroxy-2-nonenal correlate with reduced enzyme activity: mapping of modified sites by Fourier transform-ion cyclotron resonance mass spectrometry. Chem Res Toxicol, 20:1260–1268. 2007.
139.
EsterbauerH, SchaurRJ, ZollnerH. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med, 11:81–128. 1991.
140.
EstevezAG. Good science shows the way. Highlight Commentary on “Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice—a model of familial amyotrophic lateral sclerosis”Free Radic Biol Med, 43:163–164. 2007.
141.
FagniL, BockaertJ. Effects of nitric oxide on glutamate-gated channels and other ionic channels. J Chem Neuroanat, 10:231–240. 1996.
142.
FanQ, YangXC, CaoXB, WangSY, YangSL, LiuXL, GaoF. Glutathione reverses peroxynitrite-mediated deleterious effects of nitroglycerin on ischemic rat hearts. J Cardiovasc Pharmacol, 47:405–412. 2006.
143.
FaucheuxBA, MartinME, BeaumontC, HunotS, HauwJJ, AgidY, HirschEC. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J Neurochem, 83:320–330. 2002.
144.
FerranteRJ, BrowneSE, ShinobuLA, BowlingAC, BaikMJ, MacGarveyU, KowallNW, BrownRHJr., BealMF. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem, 69:2064–2074. 1997.
145.
FerranteRJ, ShinobuLA, SchulzJB, MatthewsRT, ThomasCE, KowallNW, GurneyME, BealMF. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol, 42:326–334. 1997.
146.
FerrerI. Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt-Jakob's disease. Neuropathol Appl Neurobiol, 28:441–451. 2002.
147.
FerrerI, Gomez-IslaT, PuigB, FreixesM, RibeE, DalfoE, AvilaJ. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res, 2:3–18. 2005.
148.
FerrerI, MartinezA, BlancoR, DalfoE, CarmonaM. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm, 118:821–839. 2011.
149.
FilipovicMR, StanicD, RaicevicS, SpasicM, NiketicV. Consequences of MnSOD interactions with nitric oxide: nitric oxide dismutation and the generation of peroxynitrite and hydrogen peroxide. Free Radic Res, 41:62–72. 2007.
150.
Fishman-JacobT, ReznichenkoL, YoudimMB, MandelSA. A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A. J Biol Chem, 284:32835–32845. 2009.
151.
FitzmauricePS, ShawIC, KleinerHE, MillerRT, MonksTJ, LauSS, MitchellJD, LynchPG. Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve, 19:797–798. 1996.
152.
FlintDH, TuminelloJF, EmptageMH. The inactivation of Fe-S cluster containing hydro-lyases by superoxide. J Biol Chem, 268:22369–22376. 1993.
153.
FloorE, WetzelMG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem, 70:268–275. 1998.
FoyCJ, PassmoreAP, VahidassrMD, YoungIS, LawsonJT. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM, 92:39–45. 1999.
156.
FrancisPT, PalmerAM, SnapeM, WilcockGK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry, 66:137–147. 1999.
157.
FratelliM, DemolH, PuypeM, CasagrandeS, EberiniI, SalmonaM, BonettoV, MengozziM, DuffieuxF, MicletE, BachiA, VandekerckhoveJ, GianazzaE, GhezziP. Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proc Natl Acad Sci U S A, 99:3505–3510. 2002.
158.
FrautschySA, BairdA, ColeGM. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci U S A, 88:8362–8366. 1991.
159.
FucciL, OliverCN, CoonMJ, StadtmanER. Inactivation of key metabolic enzymes by mixed-function oxidation reactions: possible implication in protein turnover and ageing. Proc Natl Acad Sci U S A, 80:1521–1525. 1983.
160.
FukuyamaH, OgawaM, YamauchiH, YamaguchiS, KimuraJ, YonekuraY, KonishiJ. Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J Nucl Med, 35:1–6. 1994.
161.
GabbitaSP, AksenovMY, LovellMA, MarkesberyWR. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. J Neurochem, 73:1660–1666. 1999.
GaneaE. Chaperone-like activity of alpha-crystallin and other small heat shock proteins. Curr Protein Pept Sci, 2:205–225. 2001.
164.
GardnerPR, NguyenDD, WhiteCW. Aconitase is a sensitive and critical target of oxygen poisoning in cultured mammalian cells and in rat lungs. Proc Natl Acad Sci U S A, 91:12248–12252. 1994.
165.
GeddesJW, PangZ, WileyDH. Hippocampal damage and cytoskeletal disruption resulting from impaired energy metabolism. Implications for Alzheimer disease. Mol Chem Neuropathol, 28:65–74. 1996.
166.
GeorgeAJ, HolsingerRM, McLeanCA, TanSS, ScottHS, CardamoneT, CappaiR, MastersCL, LiQX. Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Aging, 27:614–623. 2006.
167.
GiambattistelliF, BucossiS, SalustriC, PanettaV, MarianiS, SiottoM, VentrigliaM, VernieriF, Dell'acquaML, CassettaE, RossiniPM, SquittiR. Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease. Neurobiol Aging in press, 2011.
168.
GiassonBI, IschiropoulosH, LeeVM, TrojanowskiJQ. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med, 32:1264–1275. 2002.
169.
GiovanniniMG, CerbaiF, BellucciA, MelaniC, GrossiC, BartolozziC, NosiD, CasamentiF. Differential activation of mitogen-activated protein kinase signalling pathways in the hippocampus of CRND8 transgenic mouse, a model of Alzheimer's disease. Neuroscience, 153:618–633. 2008.
170.
GlabeCG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging, 27:570–575. 2006.
171.
GokulranganG, ZaidiA, MichaelisML, SchoneichC. Proteomic analysis of protein nitration in rat cerebellum: effect of biological aging. J Neurochem, 100:1494–1504. 2007.
172.
GolejJ, HoegerH, RadnerW, UnfriedG, LubecG. Oral administration of methylglyoxal leads to kidney collagen accumulation in the mouse. Life Sci, 63:801–807. 1998.
173.
GomezA, FerrerI. Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. J Neurosci Res, 87:1002–1013. 2009.
174.
GoshimaY, NakamuraF, StrittmatterP, StrittmatterSM. Collapsin-induced growth cone collapse mediated by an intracellular protein related to Unc-33. Nature, 376:509–514. 1995.
175.
GotzME, KunigG, RiedererP, YoudimMB. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther, 63:37–122. 1994.
176.
Grundke-IqbalI, IqbalK, QuinlanM, TungYC, ZaidiMS, WisniewskiHM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem, 261:6084–6089. 1986.
177.
GulesserianT, SeidlR, HardmeierR, CairnsN, LubecG. Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Investig Med, 49:41–46. 2001.
178.
GurneyME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci, 152,Suppl 1:S67–S73. 1997.
HalliwellB. Oxidative stress and neurodegeneration: where are we now?J Neurochem, 97:1634–1658. 2006.
181.
HalliwellB. Proteasomal dysfunction: a common feature of neurodegenerative diseases? Implications for the environmental origins of neurodegeneration. Antioxid Redox Signal, 8:2007–2019. 2006.
HellbergK, GrimsrudPA, KruseAC, BanaszakLJ, OhlendorfDH, BernlohrDA. X-ray crystallographic analysis of adipocyte fatty acid binding protein (aP2) modified with 4-hydroxy-2-nonenal. Prot Sci, 19:1480–1489. 2010.
188.
HelmanM, GivolD. Isolation of nitrotyrosine-containing peptides by using an insoluble-antibody column. Biochem J, 125:971–974. 1971.
189.
HensleyK, FedynyshynJ, FerrellS, FloydRA, GordonB, GrammasP, HamdheydariL, MhatreM, MouS, PyeQN, StewartC, WestM, WestS, WilliamsonKS. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis, 14:74–80. 2003.
190.
HensleyK, HallN, SubramaniamR, ColeP, HarrisM, AksenovM, AksenovaM, GabbitaSP, WuJF, CarneyJMet al.Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem, 65:2146–2156. 1995.
191.
Hilditch-MaguireP, TrettelF, PassaniLA, AuerbachA, PersichettiF, MacDonaldME. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet, 9:2789–2797. 2000.
192.
HillmerAS, PutchaP, LevinJ, HogenT, HymanBT, KretzschmarH, McLeanPJ, GieseA. Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. Biochem Biophys Res Commun, 391:461–466. 2010.
193.
HinkU, OelzeM, KolbP, BachschmidM, ZouMH, DaiberA, MollnauH, AugustM, BaldusS, TsilimingasN, WalterU, UllrichV, MunzelT. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol, 42:1826–1834. 2003.
HolzerM, GartnerU, StobeA, HartigW, GruschkaH, BrucknerMK, ArendtT. Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus. Acta Neuropathol, 104:471–481. 2002.
197.
HoyerS. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol, 35:1363–1372. 2000.
198.
HoyerS. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol, 490:115–125. 2004.
199.
HsuJL, ChenSH, LiDT, ShiFK. Enhanced a1 fragmentation for dimethylated proteins and its applications for N-terminal identification and comparative protein quantitation. J Proteome Res, 6:2376–2383. 2007.
200.
HuangLL, ShangF, NowellTRJr., TaylorA. Degradation of differentially oxidized alpha-crystallins in bovine lens epithelial cells. Exp Eye Res, 61:45–54. 1995.
201.
HysonHC, KieburtzK, ShoulsonI, McDermottM, RavinaB, de BlieckEA, CudkowiczME, FerranteRJ, ComoP, FrankS, ZimmermanC, FerranteK, NewhallK, JenningsD, KelseyT, WalkerF, HuntV, DaigneaultS, GoldsteinM, WeberJ, WattsA, BealMF, BrowneSE, MetakisLJ. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov Disord, 25:1924–1928. 2010.
IannelloRC, CrackPJ, de HaanJB, KolaI. Oxidative stress and neural dysfunction in Down syndrome. J Neural Transm Suppl, 57:257–267. 1999.
204.
IgnarroLJ. Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension, 16:477–483. 1990.
205.
IharaY, NobukuniK, TakataH, HayabaraT. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res, 27:105–108. 2005.
206.
IncePG, ShawPJ, CandyJM, MantleD, TandonL, EhmannWD, MarkesberyWR. Iron, selenium and glutathione peroxidase activity are elevated in sporadic motor neuron disease. Neurosci Lett, 182:87–90. 1994.
JangBG, YunSM, AhnK, SongJH, JoSA, KimYY, KimDK, ParkMH, HanC, KohYH. Plasma carbonic anhydrase II protein is elevated in Alzheimer's disease. J Alzheimers Dis JAD, 21:939–945. 2010.
209.
JennerP. Oxidative stress in Parkinson's disease. Ann Neurol, 53,Suppl 3:S26–S36. 2003discussion S36–S38.
210.
JeongSY, RathoreKI, SchulzK, PonkaP, ArosioP, DavidS. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci, 29:610–619. 2009.
211.
JiangH, LuanZ, WangJ, XieJ. Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload. Neurochem Int, 49:605–609. 2006.
212.
JoguchiA, OtsukaI, MinagawaS, SuzukiT, FujiiM, AyusawaD. Overexpression of VDUP1 mRNA sensitizes HeLa cells to paraquat. Biochem Biophys Res Commun, 293:293–297. 2002.
213.
JouvenceauA, DutarP, BillardJM. Alteration of NMDA receptor-mediated synaptic responses in CA1 area of the aged rat hippocampus: contribution of GABAergic and cholinergic deficits. Hippocampus, 8:627–637. 1998.
214.
JovanovicSV, ClementsD, MacLeodK. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med, 25:1044–1048. 1998.
215.
KahlePJ, NeumannM, OzmenL, MullerV, OdoyS, OkamotoN, JacobsenH, IwatsuboT, TrojanowskiJQ, TakahashiH, WakabayashiK, BogdanovicN, RiedererP, KretzschmarHA, HaassC. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol, 159:2215–2225. 2001.
216.
KamatCD, GadalS, MhatreM, WilliamsonKS, PyeQN, HensleyK. Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J Alzheimers Dis, 15:473–493. 2008.
217.
KanskiJ, AltermanMA, SchoneichC. Proteomic identification of age-dependent protein nitration in rat skeletal muscle. Free Radic Biol Med, 35:1229–1239. 2003.
218.
KanskiJ, HongSJ, SchoneichC. Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J Biol Chem, 280:24261–24266. 2005.
219.
KapogiannisD, MattsonMP. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol, 10:187–198. 2011.
220.
KatoS, HayashiH, NakashimaK, NanbaE, KatoM, HiranoA, NakanoI, AsayamaK, OhamaE. Pathological characterization of astrocytic hyaline inclusions in familial amyotrophic lateral sclerosis. Am J Pathol, 151:611–620. 1997.
221.
KellerJN, HanniKB, MarkesberyWR. Impaired proteasome function in Alzheimer's disease. J Neurochem, 75:436–439. 2000.
222.
KellerJN, SchmittFA, ScheffSW, DingQ, ChenQ, ButterfieldDA, MarkesberyWR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology, 64:1152–1156. 2005.
223.
KidaK, NishioT, NagaiK, MatsudaH, NakagawaH. Gluconeogenesis in the kidney in vivo in fed rats. Circadian change and substrate specificity. J Biochem (Tokyo), 91:755–760. 1982.
224.
KienzlE, JellingerK, StachelbergerH, LinertW. Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?Life Sci, 65:1973–1976. 1999.
225.
KieranD, KalmarB, DickJR, Riddoch-ContrerasJ, BurnstockG, GreensmithL. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med, 10:402–405. 2004.
226.
KimM, JungY, LeeK, KimC. Identification of the calcium binding sites in translationally controlled tumor protein. Arch Pharm Res, 23:633–636. 2000.
227.
KimSH, FountoulakisM, CairnsN, LubecG. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl61:223–235. 2001.
228.
KloseJ. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik, 26:231–243. 1975.
229.
KnyushkoTV, SharovVS, WilliamsTD, SchoneichC, BigelowDJ. 3-Nitrotyrosine modification of SERCA2a in the aging heart: a distinct signature of the cellular redox environment. Biochemistry, 44:13071–13081. 2005.
230.
KoeppenAH. The history of iron in the brain. J Neurol Sci, 134,Suppl 19. 1995.
231.
KondrikovD, ElmsS, FultonD, SuY. eNOS-beta-actin interaction contributes to increased peroxynitrite formation during hyperoxia in pulmonary artery endothelial cells and mouse lungs. J Biol Chem, 285:35479–35487. 2010.
232.
KorenbergJR, BradleyC, DistecheCM. Down syndrome: molecular mapping of the congenital heart disease and duodenal stenosis. Am J Hum Genet, 50:294–302. 1992.
233.
KorolainenMA, GoldsteinsG, AlafuzoffI, KoistinahoJ, PirttilaT. Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis, 23:3428–3433. 2002.
234.
KorolainenMA, GoldsteinsG, NymanTA, AlafuzoffI, KoistinahoJ, PirttilaT. Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging, 27:42–53. 2006.
235.
LaFontaineMA, MattsonMP, ButterfieldDA. Oxidative stress in synaptosomal proteins from mutant presenilin-1 knock-in mice: implications for familial Alzheimer's disease. Neurochem Res, 27:417–421. 2002.
LandinoLM, SkresletTE, AlstonJA. Cysteine oxidation of tau and microtubule-associated protein-2 by peroxynitrite: modulation of microtubule assembly kinetics by the thioredoxin reductase system. J Biol Chem, 279:35101–35105. 2004.
238.
LauderbackCM, HackettJM, HuangFF, KellerJN, SzwedaLI, MarkesberyWR, ButterfieldDA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J Neurochem, 78:413–416. 2001.
239.
LayfieldR, FergussonJ, AitkenA, LoweJ, LandonM, MayerRJ. Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neurosci Lett, 209:57–60. 1996.
240.
LedesmaMD, Da SilvaJS, CrassaertsK, DelacourteA, De StrooperB, DottiCG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep, 1:530–535. 2000.
241.
LeeS, YoungNL, WhetstonePA, ChealSM, BennerWH, LebrillaCB, MearesCF. Method to site-specifically identify and quantitate carbonyl end products of protein oxidation using oxidation-dependent element coded affinity tags (O-ECAT) and nanoliquid chromatography Fourier transform mass spectrometry. J Prot Res, 5:539–547. 2006.
242.
LeeSH, TakahashiR, GotoT, OeT. Mass spectrometric characterization of modifications to angiotensin II by lipid peroxidation products, 4-oxo-2(E)-nonenal and 4-hydroxy-2(E)-nonenal. Chem Res Toxicol, 23:1771–1785. 2010.
LemieuxN, MalfoyB, ForrestGL. Human carbonyl reductase (CBR) localized to band 21q22.1 by high-resolution fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cells. Genomics, 15:169–172. 1993.
LeveugleB, SpikG, PerlDP, BourasC, FillitHM, HofPR. The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res, 650:20–31. 1994.
247.
LevineRL, WehrN, WilliamsJA, StadtmanER, ShacterE. Determination of carbonyl groups in oxidized proteins. Methods Mol Biol, 99:15–24. 2000.
248.
LiYF, WangY, ChannonKM, SchultzHD, ZuckerIH, PatelKP. Manipulation of neuronal nitric oxide synthase within the paraventricular nucleus using adenovirus and antisense technology. Methods Mol Med, 112:59–79. 2005.
249.
LilligCH, HolmgrenA. Thioredoxin and related molecules—from biology to health and disease. Antioxid Redox Signal, 9:25–47. 2007.
250.
LinTK, HughesG, MuratovskaA, BlaikieFH, BrookesPS, Darley-UsmarV, SmithRA, MurphyMP. Specific modification of mitochondrial protein thiols in response to oxidative stress: a proteomics approach. J Biol Chem, 277:17048–17056. 2002.
251.
LiochevSI, FridovichI. Copper- and zinc-containing superoxide dismutase can act as a superoxide reductase and a superoxide oxidase. J Biol Chem, 275:38482–38485. 2000.
252.
LiouYC, RyoA, HuangHK, LuPJ, BronsonR, FujimoriF, UchidaT, HunterT, LuKP. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci U S A, 99:1335–1340. 2002.
253.
LiuD, WenJ, LiuJ, LiL. The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J, 13:2318–2328. 1999.
254.
LiuR, AlthausJS, EllerbrockBR, BeckerDA, GurneyME. Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann Neurol, 44:763–770. 1998.
255.
LottIT, HeadE, DoranE, BusciglioJ. Beta-amyloid, oxidative stress and down syndrome. Curr Alzheimer Res, 3:521–528. 2006.
256.
LouretteN, SmallwoodH, WuS, RobinsonEW, SquierTC, SmithRD, Pasa-TolicL. A top-down LC-FTICR MS-based strategy for characterizing oxidized calmodulin in activated macrophages. J Am Soc Mass Spectrom, 21:930–939. 2010.
LovellMA, XiongS, MarkesberyWR, LynnBC. Quantitative proteomic analysis of mitochondria from primary neuron cultures treated with amyloid beta peptide. Neurochem Res, 30:113–122. 2005.
259.
LuB, MotoyamaA, RuseC, VenableJ, YatesJR3rd. Improving protein identification sensitivity by combining MS and MS/MS information for shotgun proteomics using LTQ-Orbitrap high mass accuracy data. Anal Chem, 80:2018–2025. 2008.
260.
LubecG, NonakaM, KrapfenbauerK, GratzerM, CairnsN, FountoulakisM. Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl, 57:161–177. 1999.
261.
MacMillan-CrowLA, CrowJP, KerbyJD, BeckmanJS, ThompsonJA. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci U S A, 93:11853–11858. 1996.
MadianAG, RegnierFE. Proteomic identification of carbonylated proteins and their oxidation sites. J Proteome Res, 9:3766–3780. 2010.
264.
MagraneJ, SmithRC, WalshK, QuerfurthHW. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J Neurosci, 24:1700–1706. 2004.
MasliahE, AlfordM, DeTeresaR, MalloryM, HansenL. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol, 40:759–766. 1996.
267.
MasliahE, MalloryM, HansenL, DeTeresaR, AlfordM, TerryR. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett, 174:67–72. 1994.
MattsonMP, PedersenWA, DuanW, CulmseeC, CamandolaS. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann N Y Acad Sci, 893:154–175. 1999.
270.
Meier-RugeW, Bertoni-FreddariC, IwangoffP. Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease. Gerontology, 40:246–252. 1994.
271.
Meier-RugeW, IwangoffP, ReichlmeierK. Neurochemical enzyme changes in Alzheimer's and Pick's disease. Arch Gerontol Geriatr, 3:161–165. 1984.
272.
MessierC, GagnonM. Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav Brain Res, 75:1–11. 1996.
MirzaeiH, BaenaB, BarbasC, RegnierF. Identification of oxidized proteins in rat plasma using avidin chromatography and tandem mass spectrometry. Proteomics, 8:1516–1527. 2008.
275.
MirzaeiH, RegnierF. Affinity chromatographic selection of carbonylated proteins followed by identification of oxidation sites using tandem mass spectrometry. Anal Chem, 77:2386–2392. 2005.
276.
MirzaeiH, RegnierF. Identification and quantification of protein carbonylation using light and heavy isotope labeled Girard's P reagent. J Chromatogr A, 1134:122–133. 2006.
277.
MolinaJA, de BustosF, Jimenez-JimenezFJ, Benito-LeonJ, GasallaT, Orti-ParejaM, VelaL, BermejoF, MartinMA, CamposY, ArenasJ. Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from patients with Alzheimer's disease. Neurology, 48:636–638. 1997.
278.
MontineTJ, QuinnJF, MontineKS, KayeJA, BreitnerJC. Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. J Alzheimers Dis, 8:359–367. 2005.
279.
MorelP, TallineauC, PontcharraudR, PiriouA, HuguetF. Effects of 4-hydroxynonenal, a lipid peroxidation product, on dopamine transport and Na+/K+ ATPase in rat striatal synaptosomes. Neurochem Int, 33:531–540. 1998.
280.
MouserPE, HeadE, HaKH, RohnTT. Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. Am J Pathol, 168:936–946. 2006.
281.
MullerWE, EckertA, KurzC, EckertGP, LeunerK. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease—therapeutic aspects. Mol Neurobiol, 41:159–171. 2010.
282.
NagyZ, EsiriMM, CatoAM, SmithAD. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol, 94:6–15. 1997.
283.
NakamuraA, GotoS. Analysis of protein carbonyls with 2,4-dinitrophenyl hydrazine and its antibodies by immunoblot in two-dimensional gel electrophoresis. J Biochem, 119:768–774. 1996.
NiatsetskayaZ, BassoM, SpeerRE, McConougheySJ, CoppolaG, MaTC, RatanRR. HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid Redox Signal, 12:435–443. 2010.
286.
NikovG, BhatV, WishnokJS, TannenbaumSR. Analysis of nitrated proteins by nitrotyrosine-specific affinity probes and mass spectrometry. Anal Biochem, 320:214–222. 2003.
287.
NishiyamaA, MatsuiM, IwataS, HirotaK, MasutaniH, NakamuraH, TakagiY, SonoH, GonY, YodoiJ. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem, 274:21645–21650. 1999.
O'FarrellPH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem, 250:4007–4021. 1975.
290.
OdettiP, AngeliniG, DapinoD, ZaccheoD, GaribaldiS, Dagna-BricarelliF, PiomboG, PerryG, SmithM, TraversoN, TabatonM. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun, 243:849–851. 1998.
291.
OjikaK, TsuguY, MitakeS, OtsukaY, KatadaE. NMDA receptor activation enhances the release of a cholinergic differentiation peptide (HCNP) from hippocampal neurons in vitro. Brain Res Dev Brain Res, 106:173–180. 1998.
292.
OkaS, MasutaniH, LiuW, HoritaH, WangD, Kizaka-KondohS, YodoiJ. Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling. Endocrinology, 147:733–743. 2006.
293.
Op den VeldeW, StamFC. Some cerebral proteins and enzyme systems in Alzheimer's presenile and senile dementia. J Am Geriatr Soc, 24:12–16. 1976.
294.
OrreniusS, BurgessDH, HamptonMB, ZhivotovskyB. Mitochondria as the focus of apoptosis research. Cell Death Differ, 4:427–428. 1997.
295.
Ostrerova-GoltsN, PetrucelliL, HardyJ, LeeJM, FarerM, WolozinB. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci, 20:6048–6054. 2000.
296.
OuJ, FontanaJT, OuZ, JonesDW, AckermanAW, OldhamKT, YuJ, SessaWC, PritchardKAJr.Heat shock protein 90 and tyrosine kinase regulate eNOS NO* generation but not NO* bioactivity. Am J Physiol Heart Circ Physiol, 286:H561–H569. 2004.
297.
OwenJB, SultanaR, AluiseCD, EricksonMA, PriceTO, BuG, BanksWA, ButterfieldDA. Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Abeta accumulation in AD brain. Free Radic Biol Med, 49:1798–1803. 2010.
PanovAV, GutekunstCA, LeavittBR, HaydenMR, BurkeJR, StrittmatterWJ, GreenamyreJT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci, 5:731–736. 2002.
300.
PeiJJ, BraakH, AnWL, WinbladB, CowburnRF, IqbalK, Grundke-IqbalI. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res, 109:45–55. 2002.
301.
PerluigiM, di DomenicoF, FioriniA, CoccioloA, GiorgiA, FoppoliC, ButterfieldDA, GiorlandinoM, GiorlandinoC, SchininaME, CocciaR. Oxidative stress occurs early in Down syndrome pregnancy: a redox proteomics analysis of amniotic fluid. Prot Clin Appl, 5:167–178. 2011.
302.
PerluigiM, Fai PoonH, HensleyK, PierceWM, KleinJB, CalabreseV, De MarcoC, ButterfieldDA. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice—a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med, 38:960–968. 2005.
303.
PerluigiM, PoonHF, MaragosW, PierceWM, KleinJB, CalabreseV, CiniC, De MarcoC, ButterfieldDA. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics, 4:1849–1861. 2005.
304.
PerluigiM, SultanaR, CeniniG, Di DomenicoF, MemoM, PierceWM, CocciaR, ButterfieldDA. Redox proteomics identification of HNE-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl, 3:682–693. 2009.
305.
PerumalAS, TordzroWK, KatzM, Jackson-LewisV, CooperTB, FahnS, CadetJL. Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain. Brain Res, 504:139–141. 1989.
306.
PestovaTV, HellenCU. The structure and function of initiation factors in eukaryotic protein synthesis. Cell Mol Life Sci, 57:651–674. 2000.
307.
PetersenA, HanssonO, PuschbanZ, SappE, RomeroN, CastilhoRF, SulzerD, RiceM, DiFigliaM, PrzedborskiS, BrundinP. Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. Eur J Neurosci, 14:1425–1435. 2001.
308.
PetronisA. Alzheimer's disease and down syndrome: from meiosis to dementia. Exp Neurol, 158:403–413. 1999.
309.
PettegrewJW, PanchalingamK, KlunkWE, McClureRJ, MuenzLR. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol Aging, 15:117–132. 1994.
PlanelE, MiyasakaT, LauneyT, ChuiDH, TanemuraK, SatoS, MurayamaO, IshiguroK, TatebayashiY, TakashimaA. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J Neurosci, 24:2401–2411. 2004.
312.
PocernichCB, LangeML, SultanaR, ButterfieldDA. Nutritional approaches to modulate oxidative stress in Alzheimer's disease. Curr Alzheimer Res, 8:452–469. 2011.
313.
PoonHF, FrasierM, ShreveN, CalabreseV, WolozinB, ButterfieldDA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice—a model of familial Parkinson's disease. Neurobiol Dis, 18:492–498. 2005.
314.
PoonHF, HensleyK, ThongboonkerdV, MerchantML, LynnBC, PierceWM, KleinJB, CalabreseV, ButterfieldDA. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice—a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med, 39:453–462. 2005.
315.
RakhitR, CunninghamP, Furtos-MateiA, DahanS, QiXF, CrowJP, CashmanNR, KondejewskiLH, ChakrabarttyA. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem, 277:47551–47556. 2002.
316.
RamakrishnanP, DicksonDW, DaviesP. Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies. Neurobiol Dis, 14:251–264. 2003.
317.
RapoportSI. In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci, 249,Suppl 3:46–55. 1999.
318.
RauniyarN, ProkaiL. Detection and identification of 4-hydroxy-2-nonenal Schiff-base adducts along with products of Michael addition using data-dependent neutral loss-driven MS3 acquisition: method evaluation through an in vitro study on cytochrome c oxidase modifications. Proteomics, 9:5188–5193. 2009.
319.
ReaumeAG, ElliottJL, HoffmanEK, KowallNW, FerranteRJ, SiwekDF, WilcoxHM, FloodDG, BealMF, BrownRHJr., ScottRW, SniderWD. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet, 13:43–47. 1996.
320.
ReedT, PerluigiM, SultanaR, PierceWM, KleinJB, TurnerDM, CocciaR, MarkesberyWR, ButterfieldDA. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis, 30:107–120. 2008.
321.
ReedTT, PierceWMJr., TurnerDM, MarkesberyWR, ButterfieldDA. Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J Cell Mol Med, 13:2019–2029. 2009.
322.
ReedTT, PierceWM, MarkesberyWR, ButterfieldDA. Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res, 1274:66–76. 2009.
323.
ReinerM, BlochW, AddicksK. Functional interaction of caveolin-1 and eNOS in myocardial capillary endothelium revealed by immunoelectron microscopy. J Histochem Cytochem, 49:1605–1610. 2001.
324.
RheeSG, ChaeHZ, KimK. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med, 38:1543–1552. 2005.
RiviereS, Birlouez-AragonI, NourhashemiF, VellasB. Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int J Geriatr Psychiatry, 13:749–754. 1998.
327.
RoeMR, McGowanTF, ThompsonLV, GriffinTJ. Targeted 18O-labeling for improved proteomic analysis of carbonylated peptides by mass spectrometry. J Am Soc Mass Spectrom, 21:1190–1203. 2010.
328.
RossorMN, IversenLL, JohnsonAJ, MountjoyCQ, RothM. Cholinergic deficit in frontal cerebral cortex in Alzheimer's disease is age dependent. Lancet, 2:1422. 1981.
329.
SaigohK, WangYL, SuhJG, YamanishiT, SakaiY, KiyosawaH, HaradaT, IchiharaN, WakanaS, KikuchiT, WadaK. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet, 23:47–51. 1999.
330.
Sajdel-SulkowskaEM, MarottaCA. Alzheimer's disease brain: alterations in RNA levels and in a ribonuclease-inhibitor complex. Science, 225:947–949. 1984.
331.
SalmonM, Dedessus Le MoutierJ, WendersF, ChiariziaS, EliaersF, RemacleJ, RoyerV, PascalT, ToussaintO. Role of the PLA2-independent peroxiredoxin VI activity in the survival of immortalized fibroblasts exposed to cytotoxic oxidative stress. FEBS Lett, 557:26–32. 2004.
332.
SayreLM, ZelaskoDA, HarrisPL, PerryG, SalomonRG, SmithMA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem, 68:2092–2097. 1997.
333.
SchapiraAH. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim Biophys Acta, 1410:159–170. 1999.
334.
ScheffSW, PriceDA. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging, 24:1029–1046. 2003.
335.
ScheffSW, PriceDA. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis, 9:101–115. 2006.
336.
SchillingG, BecherMW, SharpAH, JinnahHA, DuanK, KotzukJA, SluntHH, RatovitskiT, CooperJK, JenkinsNA, CopelandNG, PriceDL, RossCA, BorcheltDR. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet, 8:397–407. 1999.
337.
SchneiderC, PorterNA, BrashAR. Autoxidative transformation of chiral omega6 hydroxy linoleic and arachidonic acids to chiral 4-hydroxy-2E-nonenal. Chem Res Toxicol, 17:937–941. 2004.
338.
SchulzePC, YoshiokaJ, TakahashiT, HeZ, KingGL, LeeRT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem, 279:30369–30374. 2004.
339.
SchutkowskiM, BernhardtA, ZhouXZ, ShenM, ReimerU, RahfeldJU, LuKP, FischerG. Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition. Biochemistry, 37:5566–5575. 1998.
SimmonsDA, CasaleM, AlconB, PhamN, NarayanN, LynchG. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia, 55:1074–1084. 2007.
350.
SinghAK, GuptaS, JiangY. Oxidative stress and protein oxidation in the brain of water drinking and alcohol drinking rats administered the HIV envelope protein, gp120. J Neurochem, 104:1478–1493. 2008.
351.
SlyWS, Hewett-EmmettD, WhyteMP, YuYS, TashianRE. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A, 80:2752–2756. 1983.
352.
SmithCD, CarneyJM, StarkereedPE, OliverCN, StadtmanER, FloydRA, MarkesberyWR. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer-disease. Proc Natl Acad Sci U S A, 88:10540–10543. 1991.
353.
SmithMA, SayreLM, AndersonVE, HarrisPL, BealMF, KowallN, PerryG. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem, 46:731–735. 1998.
354.
SmithPJ, TappelAL, ChowCK. Glutathione peroxidase activity as a function of dietary selenomethionine. Nature, 247:392–393. 1974.
355.
SmithRG, HenryYK, MattsonMP, AppelSH. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol, 44:696–699. 1998.
356.
SnellRG, MacMillanJC, CheadleJP, FentonI, LazarouLP, DaviesP, MacDonaldME, GusellaJF, HarperPS, ShawDJ. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet, 4:393–397. 1993.
357.
SorollaMA, Reverter-BranchatG, TamaritJ, FerrerI, RosJ, CabiscolE. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med, 45:667–678. 2008.
358.
SousaLP, SilvaBM, BrasilBS, NogueiraSV, FerreiraPC, KroonEG, KatoK, BonjardimCA. Plasminogen/plasmin regulates alpha-enolase expression through the MEK/ERK pathway. Biochem Biophys Res Commun, 337:1065–1071. 2005.
359.
SperandioS, PoksayKS, SchillingB, CrippenD, GibsonBW, BredesenDE. Identification of new modulators and protein alterations in non-apoptotic programmed cell death. J Cell Biochem, 111:1401–1412. 2010.
360.
StadtmanER, LevineRL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids, 25:207–218. 2003.
361.
SubramaniamR, RoedigerF, JordanB, MattsonMP, KellerJN, WaegG, ButterfieldDA. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J Neurochem, 69:1161–1169. 1997.
362.
SultanaR, Boyd-KimballD, CaiJ, PierceWM, KleinJB, MerchantM, ButterfieldDA. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis, 11:153–164. 2007.
363.
SultanaR, Boyd-KimballD, PoonHF, CaiJ, PierceWM, KleinJB, MerchantM, MarkesberyWR, ButterfieldDA. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging, 27:1564–1576. 2006.
364.
SultanaR, ButterfieldDA. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem Res, 29:2215–2220. 2004.
365.
SultanaR, ButterfieldDA. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J Bioenerg Biomembr, 41:441–446. 2009.
366.
SultanaR, ButterfieldDA. Identification of the oxidative stress proteome in the brain. Free Radic Biol Med, 50:487–494. 2011.
367.
SultanaR, MecocciP, MangialascheF, CecchettiR, BaglioniM, ButterfieldDA. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer's disease: insights into the role of oxidative stress in Alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder. J Alzheimers Dis, 24:77–84. 2011.
368.
SultanaR, PerluigiM, ButterfieldDA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal, 8:2021–2037. 2006.
369.
SultanaR, PerluigiM, ButterfieldDA. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol, 118:131–150. 2009.
370.
SultanaR, PerluigiM, NewmanSF, PierceWM, CiniC, CocciaR, ButterfieldDA. Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease. Antioxid Redox Signal, 12:327–336. 2010.
371.
SultanaR, PoonHF, CaiJ, PierceWM, MerchantM, KleinJB, MarkesberyWR, ButterfieldDA. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis, 22:76–87. 2006.
372.
SultanaR, ReedT, PerluigiM, CocciaR, PierceWM, ButterfieldDA. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J Cell Mol Med, 11:839–851. 2007.
373.
SurmeliNB, LittermanNK, MillerAF, GrovesJT. Peroxynitrite mediates active site tyrosine nitration in manganese superoxide dismutase. Evidence of a role for the carbonate radical anion. J Am Chem Soc, 132:17174–17185. 2010.
374.
SuzukiYJ, CariniM, ButterfieldDA. Protein carbonylation. Antioxid Redox Signal, 12:323–325. 2010.
375.
SzaboC. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett, 140–141:105–112. 2003.
376.
TamaritJ, CabiscolE, RosJ. Identification of the major oxidatively damaged proteins in Escherichia coli cells exposed to oxidative stress. J Biol Chem, 273:3027–3032. 1998.
377.
TempleA, YenTY, GronertS. Identification of specific protein carbonylation sites in model oxidations of human serum albumin. J Am Soc Mass Spectrom, 17:1172–1180. 2006.
ThompsonJE, HopkinsMT, TaylorC, WangTW. Regulation of senescence by eukaryotic translation initiation factor 5A: implications for plant growth and development. Trends Plant Sci, 9:174–179. 2004.
380.
ThompsonKJ, ShohamS, ConnorJR. Iron and neurodegenerative disorders. Brain Res Bull, 55:155–164. 2001.
381.
TrettelF, RigamontiD, Hilditch-MaguireP, WheelerVC, SharpAH, PersichettiF, CattaneoE, MacDonaldME. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet, 9:2799–2809. 2000.
382.
TrujilloM, FolkesL, BartesaghiS, KalyanaramanB, WardmanP, RadiR. Peroxynitrite-derived carbonate and nitrogen dioxide radicals readily react with lipoic and dihydrolipoic acid. Free Radic Biol Med, 39:279–288. 2005.
383.
TsujimotoKH, KawaiT, MatsumotoH. Oxidized protein quantitation method using isotope-substituted labeling reagent and mass spectrometrypp 2007-JP55617 2007111193, 2020070320.
384.
UchidaK, StadtmanER. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction. J Biol Chem, 268:6388–6393. 1993.
385.
ValenciaCA, JuW, LiuR. Matrin 3 is a Ca2+/calmodulin-binding protein cleaved by caspases. Biochem Biophys Res Commun, 361:281–286. 2007.
386.
ValenteEM, SalviS, IalongoT, MarongiuR, EliaAE, CaputoV, RomitoL, AlbaneseA, DallapiccolaB, BentivoglioAR. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol, 56:336–341. 2004.
387.
ValentineJS. Do oxidatively modified proteins cause ALS?Free Radic Biol Med, 33:1314–1320. 2002.
388.
Van LaarVS, DukesAA, CascioM, HastingsTG. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis, 29:477–489. 2008.
389.
VanaL, KanaanNM, HakalaK, WeintraubST, BinderLI. Peroxynitrite-induced nitrative and oxidative modifications alter tau filament formation. Biochemistry, 50:1203–1212. 2011.
390.
VayssiereJL, Cordeau-LossouarnL, LarcherJC, BassevilleM, GrosF, CroizatB. Participation of the mitochondrial genome in the differentiation of neuroblastoma cells. In Vitro Cell Dev Biol, 28A:763–772. 1992.
VilaA, TallmanKA, JacobsAT, LieblerDC, PorterNA, MarnettLJ. Identification of protein targets of 4-hydroxynonenal using click chemistry for ex vivo biotinylation of azido and alkynyl derivatives. Chem Res Toxicol, 21:432–444. 2008.
393.
VinerRI, FerringtonDA, WilliamsTD, BigelowDJ, SchoneichC. Protein modification during biological aging: selective tyrosine nitration of the SERCA2a isoform of the sarcoplasmic reticulum Ca2+-ATPase in skeletal muscle. Biochem J, 340,Pt 3:657–669. 1999.
394.
WallimannT, HemmerW. Creatine kinase in non-muscle tissues and cells. Mol Cell Biochem, 133–134:193–220. 1994.
395.
WangJ, XuG, GonzalesV, CoonfieldM, FromholtD, CopelandNG, JenkinsNA, BorcheltDR. Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol Dis, 10:128–138. 2002.
WangXS, LeeS, SimmonsZ, BoyerP, ScottK, LiuW, ConnorJ. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci, 227:27–33. 2004.
398.
WatanabeM, Dykes-HobergM, CulottaVC, PriceDL, WongPC, RothsteinJD. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis, 8:933–941. 2001.
399.
WeitzdoerferR, FountoulakisM, LubecG. Aberrant expression of dihydropyrimidinase related proteins-2,-3 and 4 in fetal Down syndrome brain. J Neural Transm Suppl, 61:95–107. 2001.
400.
WinklhoferKF. The parkin protein as a therapeutic target in Parkinson's disease. Expert Opin Ther Targets, 11:1543–1552. 2007.
401.
WinterbournCC, BussIH. Protein carbonyl measurement by enzyme-linked immunosorbent assay. Methods Enzymol, 300:106–111. 1999.
402.
YamakuraF, MatsumotoT, FujimuraT, TakaH, MurayamaK, ImaiT, UchidaK. Modification of a single tryptophan residue in human Cu,Zn-superoxide dismutase by peroxynitrite in the presence of bicarbonate. Biochim Biophys Acta, 1548:38–46. 2001.
403.
YamashiroS, YamakitaY, OnoS, MatsumuraF. Fascin, an actin-bundling protein, induces membrane protrusions and increases cell motility of epithelial cells. Mol Biol Cell, 9:993–1006. 1998.
404.
YangL, CalingasanNY, WilleEJ, CormierK, SmithK, FerranteRJ, BealMF. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem, 109:1427–1439. 2009.
405.
YarianCS, RebrinI, SohalRS. Aconitase and ATP synthase are targets of malondialdehyde modification and undergo an age-related decrease in activity in mouse heart mitochondria. Biochem Biophys Res Commun, 330:151–156. 2005.
406.
YooBS, RegnierFE. Proteomic analysis of carbonylated proteins in two-dimensional gel electrophoresis using avidin-fluorescein affinity staining. Electrophoresis, 25:1334–1341. 2004.
407.
YoritakaA, HattoriN, UchidaK, TanakaM, StadtmanER, MizunoY. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A, 93:2696–2701. 1996.
408.
YoshidaH, WatanabeA, IharaY. Collapsin response mediator protein-2 is associated with neurofibrillary tangles in Alzheimer's disease. J Biol Chem, 273:9761–9768. 1998.
409.
ZeitlinS, LiuJP, ChapmanDL, PapaioannouVE, EfstratiadisA. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet, 11:155–163. 1995.
410.
ZhangSM, HernanMA, ChenH, SpiegelmanD, WillettWC, AscherioA. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology, 59:1161–1169. 2002.
411.
ZhouJ, YuQ, ChngWJ. TXNIP (VDUP-1, TBP-2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms. Int J Biochem Cell Biol, 43:1668–1673. 2011.
412.
ZhouXZ, KopsO, WernerA, LuPJ, ShenM, StollerG, KullertzG, StarkM, FischerG, LuKP. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell, 6:873–883. 2000.
